

ISSUE @ A GLANCE



Challenges in heart failure: quality of life, chronic kidney disease, and secondary mitral regurgitation

F. Crea

1185

CardioPulse

Development and current status of Interventional cardiology in Sudan

A.A.A. Suliman

1190

The Year in Cardiovascular Medicine 2020: Coronary Prevention

M. Nicholls

1192

The Rajaie Cardiovascular Medical and Research Centre

B. Mohebbi, B. Ghadrdoost, and P. Sadeghipour

1194

Weekly Journal Scan

Glucocorticoids in patients with immune-mediated inflammatory diseases: a neglected cardiovascular risk factor

L. Galiuto and M. Volpe

1197

VIEWPOINT

Heart Failure and Cardiomyopathies

The Dapagliflozin and Prevention of Adverse outcomes in Heart Failure trial (DAPA-HF) in context

J.J.V. McMurray, S.D. Solomon, K.F. Docherty, and P.S. Jhund

1199


CLINICAL RESEARCH

Heart Failure and Cardiomyopathies
Empagliflozin and health-related quality of life outcomes in patients with heart failure with reduced ejection fraction: the EMPEROR-Reduced trial

J. Butler, S.D. Anker, G. Filippatos, M.S. Khan, J.P. Ferreira, S.J. Pocock, N. Giannetti, J.L. Januzzi, I.L. Piña, C.S.P. Lam, P. Ponikowski, N. Sattar, S. Verma, M. Brueckmann, W. Jamal, O. Vedin, B. Peil, C. Zeller, F. Zannad, and M. Packer; on behalf of the EMPEROR-Reduced Trial Committees and Investigators

1203

Responder analysis for KCCQ-CSS at 3, 6, and 12 months



Editorial

Quality of life in EMPEROR-Reduced: emphasizing what is important to patients while identifying strategies to support more patient-centred care

J.A. Spertus

1213

Heart Failure and Cardiomyopathies
Effects of dapagliflozin on mortality in patients with chronic kidney disease: a pre-specified analysis from the DAPA-CKD randomized controlled trial

H.J.L. Heerspink, C.D. Sjöström, N. Jongs, G.M. Chertow, M. Kosiborod, F.F. Hou, J.J.V. McMurray, P. Rossing, R. Correa-Rotter, R. Kurlyandskaya, B.V. Stefansson, R.D. Toto, A.M. Langkilde, and D.C. Wheeler; for the DAPA-CKD Trial Committees and Investigators

1216

Editorial

Dapagliflozin, advanced chronic kidney disease, and mortality: new insights from the DAPA-CKD trial

N. Marx and J. Floege


1228

CLINICAL REVIEW

Heart Failure and Cardiomyopathies

Arrhythmogenic right ventricular cardiomyopathy and sports activity: from molecular pathways in diseased hearts to new insights into the athletic heart mimicry

A. Gasperetti, C.A. James, M. Cerrone, M. Delmar, H. Calkins, and F. Duru



Heart Failure and Cardiomyopathies

The cardiovascular-dialysis nexus: the transition to dialysis is a treacherous time for the heart

K. Chan, S.M. Moe, R. Saran, and P. Libby

1244

SPECIAL ARTICLE

- 8 The management of secondary mitral regurgitation in patients with heart failure: a joint position statement from the Heart Failure Association (HFA), European Association of Cardiovascular Imaging (EACVI), European Heart Rhythm Association (EHRA), and European Association of Percutaneous Cardiovascular Interventions (EAPCI) of the ESC

A.J.S. Coats, S.D. Anker, A. Baumbach, O. Alfieri, R.S. von Bardeleben, J. Bauersachs, J.J. Bax, S. Boveda, J. Čelutkienė, J.G. Cleland, N. Dagres, T. Deneke, D. Farmakis, G. Filippatos, J. Hausleiter, G. Hindricks, E.A. Jankowska, M. Lainscak, C. Leclercq, L.H. Lund, T. McDonagh, M.R. Mehra, M. Metra, N. Mewton, C. Mueller, W. Mullens, C. Muneretto, J.-F. Obadia, P. Ponikowski, F. Praz, V. Rudolph, F. Ruschitzka, A. Vahanian, S. Windecker, J.L. Zamorano, T. Edvardsen, H. Heidbuchel, P.M. Seferovic, and B. Prendergast

1254

DISCUSSION FORUM

Different genotypes of Brugada syndrome may present different clinical phenotypes: electrophysiology from bench to bedside

I. El-Battrawy, S. Lang, X. Zhou, and I. Akin

1270

- 8 Common modulators of Brugada syndrome phenotype do not affect SCN5A prognostic value

C. Pappone, G. Cicconte, E. Micaglio, and M.M. Monasky

1273

CARDIOVASCULAR FLASHLIGHT

Thrombus in giant right atrial appendage aneurysm

H. Niu, J. Shen, W. Liang, and Z. Xiao

1275

Cardiac angiosarcoma detected using ^{68}Ga -fibroblast activation protein inhibitor positron emission tomography/magnetic resonance

L. Zhao, Y. Pang, Q. Lin, and H. Chen

1276

CORRECTIONS

Corrigendum to: Gone with wind: a novel biodegradable occluder for percutaneous closure of patent foramen ovale

1269

Erratum to: Arrhythmogenic Right Ventricular Cardiomyopathy and Sports Activity: From Molecular Pathways in Diseased Hearts to New Insights into the Athletic Heart Mimicry

1272

Corrigendum to: How to Diagnose Heart Failure with Preserved Ejection Fraction - The HFA-PEFF-SCORE An updated Consensus Statement of the Heart Failure Association (HFA) of the European Society of Cardiology (ESC)

1274



Open Access Paper



For the podcast associated with this article, please visit <https://academic.oup.com/eurheartj/pages/Podcasts>



Visit EHJ's mobile site

<https://academic.oup.com/eurheartj>



www.eurheartj.org